Medication consumption in diabetes mellitus (VI). Economics and effectiveness of insulin and sulfonylurea combination therapy compared with conventional two-daily doses;Consumo de medicacion en la diabetes mellitus (VI). Economia y efectividad de la terapia combinada con insulina y sulfonilureas sobre la administracion convencional con dos dosis

Medicina Clinica

Volumn 111, Issue 15, 1998, Pages 568-572

  Costa, Bernardo ^a   Estopá, Assumpció ^a   Borrás, Joanna ^a   Sabaté, Àngels ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; INSULIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; WEIGHT GAIN; BODY MASS; COMPARATIVE STUDY; COST OF ILLNESS; DRUG COMBINATION; FOLLOW UP; HOSPITALIZATION; INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY;

BODY MASS INDEX; COST OF ILLNESS; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SULFONYLUREA COMPOUNDS;

EID: 0032494585     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Shank ML, Del Prato S, De Fronzo RA. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. Diabetes 1995; 44: 165-172.
2. De Fronzo RA. Ferranini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
3. Gruesser M, Bott U, Ellermann P, Kronsbein P, Jörgens V. Evaluation of a structured treatment and teaching program for non-insulin-treated type II diabetic outpatients in Germany after the nationwide introduction of reimbursement policy for physicians. Diabetes Care 1993; 16: 1.268-1.275.
4. Yki-Jarvinen H, Kauppila M, Kujansuue E. Comparison of insulin regimens in patients with NIDDM. N Engl J Med 1992; 327; 1426-1433.
5. Costa B, Utgés P, Monclús JF, Gomis T, Ciurana MR, Julve P y el Grup per a l'Estudi de la Diabetis a Tarragona (GEDT). Consume de medicación en la diabetes mellitus (I). Estimación del perfil terapéutico y la prevalencia en Tarragona. Med Clin (Barc) 1992; 99: 294-299.
6. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996; 156: 259-264.
7. Ersser RS, Barlow GB, Drew RG, Hjelm M. Automated quantitative, low pressure, cation-exchange chromatography of haemoglobin variants of midget columns. J Autom Chem 1987; 9: 92-96.
8. Costa B, Estopá A, Borrás J, Sabaté A. Diabetes y farmacoeconomia. Eficiencia de los sistemas disponibles para la inyección de insulina en España. Aten Primaria 1995; 16; 391-396.
9. Groop LC, Pelkonen R, Koskimies S, Botazzo GF, Doniach D. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 1986; 9: 129-133.
10. Simpson H, Sturkey R, Stirling C, Reckless J. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients. Diabet Med 1990; 7: 143-147.
11. Mezitis N, Heshka S, Saitas V, Bailey TS, Costa R, Pi-Sunyer FX. Combination therapy for NIDDM with byosinthetic human insulin and glyburide. Diabetes Care 1992; 15: 265-269.
12. Papoz L, Eurodiab Subarea C Study Group. Utilization of drug sales data for the epidemiology of chronic diseases: The example of diabetes. Epidemiology 1993; 4: 421-427.
13. Féry F, Desir D, Mockel I. Residual affects of a short-term intensified insulin therapy in type II diabetic patients with oral drug failure. Diabete Metab 1991; 17: 525-529.
14. Pasmantier R, Chaiken R, Hirsch S, Lebovitz H. Metabolic effects of combination glipizide and human proinsulin treatment in NIDDM. Diabetes Care 1990; 13 (Supl 3): 42-46.
15. Riddle MC, Hart JS. Which patients might benefit from combining a sulfonylurea with insulin? Diabetes Care 1985; 8: 204-205.
16. Riddle MC, Hart JS, Bouma DJ, Phillipson BE, Youker G. Efficacy of bedtime NPH insulin with daytime sulfonylurea for a subpopulation of type II diabetes. Diabetes Care 1989; 12: 623-629.
17. Landsted-Hallin L, Adamson U, Amer P. Bolinder J, Lins PE. Comparison of bedtime NPH or regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995; 18: 1.183-1.186.
18. Liu D, Wettergren M, Lins PE, Adamson U. Combined insulin-glibenclamide therapy of NIDDM patients in primary health care. A follow-up study of its compliance and efficacy and a review of the literature. Scand J Prim Health Care 1990; 8: 213-217.
19. Costa B, Arroyo J, Sabaté A. The economics of pharmacotherapy for diabetes mellitus. PharmacoEconomics 1997; 11: 139-158.
20. Alberti KGMM, Gries FA, Jervell J. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM): an update. Diabet Med 1994; 11: 899-909.
21. Groop LC, Widen E, Ekstrand A, Saloranta C, Franssila-Kallunki A, Schalin-Jantti C et al. Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM. Diabetes Care 1992; 15: 831-834.
22. Sotaniemi EA, Vierimaa E, Huupponen R, Karvonen I, Vuoti MJ, Rytömaa K. Insulin and sulfonylurea in the therapy of type II diabetes. Diabetes Res Clin Pract 1990; 8: 243-251.
23. Vigneri R, Trischitta V, Italia S, Mazzarino S, Rabuazzo MA, Squatrito S. Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bedtime NPH insulin to glyburide. Diabete Metab 1991; 17: 232-234.
24. Trischitta V, Italia S, Mazzarino S, Buscena M, Rabuazzo MA, Sangiorgio S et al. Comparison of combined therapies in treatment of secondary failure to glyburide. Diabetes Care 1992; 15: 539-542.
25. Soneru IL, Agrawal L, Lawrence AM, Abraira C. Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure. Diabetes Care 1993; 16: 895-901.